Learn more about whether Recursion Pharmaceuticals, Inc. or Zai Lab Limited is a better investment based on AAII's A+ ...

Fintel reports that on March 3, 2025, B of A Securities downgraded their outlook for Zai Lab Limited - Depositary Receipt () (NasdaqGM:ZLAB) from Buy to Neutral. Analyst Price Forecast Suggests 14 ...

Zai Lab is actively participating in the Greater ... Povetacicept is a novel dual BAFF, B-cell activating factor and APRIL, a proliferation-inducing ligand antagonist with best-in-class potential ...

ISLAMABAD: The Senate Standing Committee on Information Technology and Telecommunication has decided to hold a dedicated ...